Barron's Bounce: Sarepta's Soaring Fortunes
The biotech stock's shares surged after Barron's said the market is underestimating potential sales of its Duchenne Muscular ...
Stocktwits on MSN4d
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up
Shares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...
Patient dies following muscular dystrophy gene therapy, Sarepta reports
A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...
MPR1d
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
GEN - Genetic Engineering and Biotechnology News1d
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Gene-Therapy Maker Sarepta Tanks After Patient Death
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for a rare muscular dystrophy.
Scotiabank Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...
This Is What Whales Are Betting On Sarepta Therapeutics
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...
Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...